NasdaqGM:PSNLLife Sciences
Personalis’ CE-IVD Win Raises Questions On MRD Traction In Europe
Personalis, trading on NasdaqGM:PSNL, has received Class A CE-IVD marking for its EDTA and cfDNA Blood Collection Kits under the EU In Vitro Diagnostic Regulation.
The certification enables the kits to be used in clinical trials across the EU and Great Britain for its ultrasensitive minimal residual disease, or MRD, testing.
This regulatory step supports wider international adoption of Personalis' oncology testing platform in large, multi country studies.
For investors tracking...